Figure 3
From: Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
A. Forced Expiratory Volume in 1 second (FEV1) over treatment period. B. Forced Vital Capacity (FVC) over treatment period. C. Gastroesophageal Symptom Assessment Score (GSAS) over treatment period. D. Cystic Fibrosis Quality of Life – revised (CFQ-R) score over treatment period. Blue lines: esomeprazole group; mean with standard deviation. Red lines: placebo group; mean with standard deviation.